Literature DB >> 21367964

Quality of life in thyroid eye disease: impact of quality of care.

Stephanie Estcourt1, Anthony G Quinn, Bijay Vaidya.   

Abstract

Thyroid eye disease (TED) is a chronic debilitating condition causing physical discomfort, facial disfigurement and impaired visual function. The physical consequences of TED could have a negative and lasting impact on patients' employment, hobbies and psychosocial function. In this review, we assess the evidence of the impact of TED on patients' quality of life (QOL) and also explore the effects of suboptimal quality of care on QOL of patients with this disease. It is hoped that recent initiatives, including the Amsterdam declaration, to raise the quality of care for patients with TED will help to improve their QOL.

Entities:  

Mesh:

Year:  2011        PMID: 21367964     DOI: 10.1530/EJE-11-0055

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  20 in total

1.  Update on advanced imaging options for thyroid-associated orbitopathy.

Authors:  Michael P Rabinowitz; Jacqueline R Carrasco
Journal:  Saudi J Ophthalmol       Date:  2012-10

2.  Changing trend in referral to secondary care specialist thyroid eye disease clinic following the Amsterdam declaration.

Authors:  Annika S Quinn; Leticia R Dujardin; Bridget Knight; James Benzimra; Anthony G Quinn; Bijay Vaidya
Journal:  Int Ophthalmol       Date:  2017-02-08       Impact factor: 2.031

3.  Measuring quality of life in oculoplastic patients.

Authors:  Edward Ridyard; Clare Inkster
Journal:  Int J Ophthalmol       Date:  2014-02-18       Impact factor: 1.779

4.  Altered spontaneous brain activity patterns in patients with hyperthyroidism exophthalmos using amplitude of low-frequency fluctuation: a resting-state fMRI study.

Authors:  Ling Ling; Wen-Feng Liu; Yu Guo; Rong-Bin Liang; Hui-Ye Shu; Li-Juan Zhang; Qiu-Yu Li; Qian-Min Ge; Yi-Cong Pan; Yi Shao
Journal:  Int J Ophthalmol       Date:  2021-12-18       Impact factor: 1.779

5.  Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Authors:  Mario Salvi; Guia Vannucchi; Nicola Currò; Irene Campi; Danila Covelli; Davide Dazzi; Simona Simonetta; Claudio Guastella; Lorenzo Pignataro; Sabrina Avignone; Paolo Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2014-12-15       Impact factor: 5.958

6.  Does thyroid surgery for Graves' disease improve health-related quality of life?

Authors:  Gregorio Scerrino; Giuditta Morfino; Nunzia Cinzia Paladino; Valentina Di Paola; Emanuele Amodio; Gaspare Gulotta; Sebastiano Bonventre
Journal:  Surg Today       Date:  2012-12-11       Impact factor: 2.549

7.  Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections.

Authors:  Sung Jun Lee; Tyler Hyung Taek Rim; Sun Young Jang; Chan Yun Kim; Dong Yeob Shin; Eun Jig Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-12       Impact factor: 3.117

8.  Thyroid-Related Orbital Decompression Surgery: A Multivariate Analysis of Risk Factors and Outcomes.

Authors:  Chris Y Wu; Leslie M Niziol; David C Musch; Alon Kahana
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2017 May/Jun       Impact factor: 1.746

Review 9.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

10.  A 'Real Life' Service Evaluation Model for Multidisciplinary Thyroid Eye Services.

Authors:  Soma Farag; Claire Feeney; Vickie Lee; Sonali Nagendran; Rajni Jain; Ahmad Aziz; Rashmi Akishar; Vassiliki Bravis; Karim Meeran
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-07       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.